Shyamakant Giri Appointed CEO of Apothecon Group

Apothecon Group has appointed Shyamakant Giri as its new Group CEO, effective May 11, 2026. Based in Vadodara, India, Giri will lead the group's growth and strategic expansion. Apothecon, supported by Everstone Capital, focuses on pharmaceuticals and healthcare, with Giri bringing 25 years of industry leadership experience.

Apothecon Group has announced Shyamakant Giri as the new Chief Executive Officer, effective May 11, 2026. With a base in Vadodara, India, Giri is set to drive the company's forthcoming growth and strategic expansion phases.

Supported by Everstone Capital, a key player in investment across high-growth sectors, Apothecon Group specializes in pharmaceutical and healthcare market solutions. Mr. Giri, with over 25 years in leadership roles within pharmaceuticals and healthcare, joins from Gland Pharma Limited where he was CEO.

Giri expressed his enthusiasm, stating that the group's development, manufacturing, and marketing strengths in complex generic drugs provide a robust platform for further growth. The company aims to leverage his expertise in their bid to strengthen their global marketplace presence.